DAX23.591 -0,9%Est505.720 -1,1%MSCI World4.343 -0,1%Top 10 Crypto8,7500 -1,6%Nas22.388 -1,6%Bitcoin58.463 -0,3%Euro1,1619 ±0,0%Öl92,69 +9,9%Gold5.171 +1,7%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
freenet A0Z2ZZ AIXTRON A0WMPJ E.ON ENAG99 Münchener Rückversicherungs-Gesellschaft 843002 Heidelberg Materials 604700 Tesla A1CX3T Vonovia A1ML7J BioNTech (ADRs) A2PSR2 NEL ASA A0B733 AMD (Advanced Micro Devices) 863186 RWE 703712 Airbus 938914 Rolls-Royce A1H81L TKMS thyssenkrupp Marine Systems TKMS00 Micron Technology 869020
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Iran-Krieg weitet sich aus: DAX geht schwach ins Wochenende -- US-Börsen tiefer -- Lufthansa auf Wachstumskurs -- US-Chipaktien, TeamViewer, Oracle, Rüstungsaktien, Marvell, DroneShield im Fokus
Top News
KW 10: Die Gewinner und Verlierer der MDAX-Aktien der vergangenen Woche KW 10: Die Gewinner und Verlierer der MDAX-Aktien der vergangenen Woche
Quantencomputer-ETFs auf dem Vormarsch: Eine Zukunftswette mit offenem Ausgang Quantencomputer-ETFs auf dem Vormarsch: Eine Zukunftswette mit offenem Ausgang
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

AbbVie Aktie

Kaufen
Verkaufen
AbbVie Aktien-Sparplan
198,40 EUR -2,00 EUR -1,00 %
BMN
229,44 USD -0,63 USD -0,27 %
nachbörslich
BTT
finanzen.net zero
AbbVie jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.353,59 Mrd. EUR

KGV96,78Div. Rendite2,91%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA1J84E

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS00287Y1091

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolABBV

AbbVie Aktien News

DatumMeistgelesen
PR NewswireAbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans
PR NewswireAbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors
PR NewswireWest Signs Agreement to Sell the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System to AbbVie
Wer­bungAbbVie-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireAbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States
PR NewswireAbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call
PR NewswireMAVIRET® receives Health Canada Approval for the Treatment of Acute Hepatitis C Virus
PR NewswireAbbVie to Present at the 44th Annual J.P. Morgan Healthcare Conference
PR NewswireAbbVie Ranked #15 in the Inaugural Fortune 100 Best Companies to Work For Southeast Asia 2025 List
PR NewswireAbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers
PR NewswireAbbVie präsentiert auf dem 19. European Headache Congress Phase-3-Daten aus der ECLIPSE-Studie, die die Überlegenheit von Atogepant (AQUIPTA®) gegenüber Placebo bei der Schmerzlinderung in der Aku...
PR NewswireAbbVie to Present Phase 3 ECLIPSE Data Demonstrating Atogepant (AQUIPTA®) Superiority Over Placebo in Achieving Pain Freedom for the Acute Treatment of Migraine at the 19th European Headache Congress
PR NewswireAbbVie to Present at the Piper Sandler 37th Annual Healthcare Conference
PR NewswireAbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma
PR NewswireLUPRON DEPOT® new strength receives Health Canada Approval for the Treatment of Advanced Prostate Cancer
PR NewswireAbbVie Partners with Award-Winning Filmmaker on Film About the Dynamic and Resilient Lives of Those Living with Blood Cancer
PR NewswireAbbVie Announces 20 Recipients of Migraine Career Catalyst Award™
PR NewswireAllergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence
PR NewswireELAHERE® Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Certain Types of Platinum-Resistant Ovarian Cancers
PR NewswireThe One & Only BOTOX® Cosmetic (onabotulinumtoxinA) Day Returns November 19 with the Biggest Celebration of the Year
PR NewswireAbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo
PR NewswireThe Confidence Project by BOTOX® Cosmetic (onabotulinumtoxinA) Unveils This Year's Grant Recipients
PR NewswireRINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor
PR NewswireAbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin
PR NewswireU.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (upadacitinib) for the Treatment of Inflammatory Bowel Disease
PR NewswireAbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors
PR NewswireSkinMedica® Debuts Reimagined Packaging and Unveils New HA5® Hydra Collagen Water Burst Moisturizer
PR NewswireAbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor
PR NewswireAbbVie to Host Third-Quarter 2025 Earnings Conference Call
PR NewswireAbbVie Begins Construction on $70 Million Expansion to Further Increase Biologics Manufacturing and R&D Presence in the U.S.
PR NewswireAbbVie Submits Biologics License Application (BLA) to U.S. FDA for Pivekimab sunirine (PVEK) - an Investigational Antibody-Drug Conjugate (ADC) to Treat Rare Cancer with Limited Treatment Options
PR NewswireAbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility
PR NewswireAbbVie Announces UK Pricing Strategy for ELAHERE® (mirvetuximab soravtansine-gynx)
PR NewswireAbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson's Disease
PR NewswireQULIPTA® (atogepant) Now Publicly Reimbursed in Quebec for Chronic Migraine and CGRP Class Review Published
PR NewswireAllergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality at AMWC Dubai
PR NewswireAllergan Aesthetics Announces Expansion of SKINVIVE by JUVÉDERM® into 35 New Markets, Reinforcing its Commitment to Advancing Global Skin Quality
PR NewswireAbbVie's VRAYLAR® (cariprazine) Now Publicly Reimbursed in Alberta
PR NewswireAbbVie Declares Quarterly Dividend
PR NewswireAbbVie Announces Updated Results From Phase 2 EPCORE® NHL-6 Study Evaluating the Potential for Outpatient Monitoring of Epcoritamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell ...
PR NewswireAllergan Aesthetics Launches Campaign to Educate Consumers about Hyaluronic Acid (HA) Injectable Fillers

AbbVie News

AbbVie News: auf dieser Seite finden Sie alle AbbVie News und Nachrichten zur AbbVie Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch AbbVie News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um AbbVie News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.